Safety and Efficacy Study Comparing ABT-335 Coadministered With Atorvastatin and Ezetimibe to Atorvastatin Coadministered With Ezetimibe in Subjects With Multiple Abnormal Lipid (Fat) Levels in the Blood

This study has been completed.

Study NCT00639158 Information provided by Abbott

First Received: March 14, 2008 Last Updated: November 16, 2009 History of Changes

Study Type:	Interventional
Study Design:	Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Parallel Assignment
Conditions:	Dyslipidemias Coronary Heart Disease Combined (Atherogenic) Dyslipidemia Mixed Dyslipidemia
Interventions:	Drug: ABT-335 Drug: placebo Drug: atorvastatin Drug: ezetimibe

Participant Flow

Hide Participant Flow

Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
One subject was randomized to the atorvastatin and ezetimibe treatment group and never received study drug.

Reporting Groups

	Description
ABT-335 + 40 mg Atorvastatin + 10 mg Ezetimibe	No text entered.
Placebo + 40 mg Atorvastatin + 10 mg Ezetimibe	No text entered.

Participant Flow: Overall Study

	ABT-335 + 40 mg Atorvastatin + 10 mg Ezetimibe	Placebo + 40 mg Atorvastatin + 10 mg Ezetimibe
STARTED	272^[1]	270^[2]
COMPLETED	246^[3]	240^[4]
NOT COMPLETED	26	30

[1]	All randomized subjects were treated.
[2]	1 subject was randomized but not treated because of an abnormal ECG that precluded treatment.
[3]	26 subjects prematurely discontinued treatment.
[4]	30 subjects prematurely discontinued treatment

Baseline Characteristics

Hide Baseline Characteristics

Reporting Groups

	Description
ABT-335 + 40 mg Atorvastatin + 10 mg Ezetimibe	No text entered.
Placebo + 40 mg Atorvastatin + 10 mg Ezetimibe	No text entered.

Baseline Measures

	ABT-335 + 40 mg Atorvastatin + 10 mg Ezetimibe	Placebo + 40 mg Atorvastatin + 10 mg Ezetimibe	Total
Number of Participants [units: participants]	272	270	542
Age [units: participants]
<=18 years	0	0	0
Between 18 and 65 years	227	206	433
>=65 years	45	64	109
Age [units: years] Mean ± Standard Deviation	54.4 ± 11.23	56.4 ± 10.67	55.4 ± 10.99
Gender [units: participants]
Female	143	155	298
Male	129	115	244
Region of Enrollment [units: participants]
United States	272	270	542

Outcome Measures

Show All Outcome Measures

1. Primary:

Median Percent Change in Triglycerides From Baseline to Final Visit [ Baseline to 12 Weeks (Final Visit) ]

Show Outcome Measure 1

2. Primary:

Mean Percent Change in High-Density Lipoprotein Cholesterol (HDL-C) From Baseline to Final Visit [ Baseline to 12 weeks (Final Visit) ]

Show Outcome Measure 2

3. Secondary:

Mean Percent Change in Apolipoprotein AI (apoAI) From Baseline to Final Visit [ Baseline to 12 weeks (Final Visit) ]

Show Outcome Measure 3

4. Secondary:

Mean Percent Change in Very Low-Density Lipoprotein Cholesterol (VLDL-C) From Baseline to Final Visit [ Baseline to 12 weeks (final visit) ]

Show Outcome Measure 4

5. Secondary:

Mean Percent Change in Apolipoprotein CIII (apoCIII) From Baseline to Final Visit [ Baseline to 12 weeks (Final Visit) ]

Hide Outcome Measure 5

Measure Type	Secondary
Measure Title	Mean Percent Change in Apolipoprotein CIII (apoCIII) From Baseline to Final Visit
Measure Description	[(Week 12 apoCIII minus baseline apoCIII)/baseline apoCIII] x 100
Time Frame	Baseline to 12 weeks (Final Visit)
Safety Issue	No

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
All randomized subjects with a baseline apoCIII value and at least 1 postbaseline apoCIII value, last observation carried forward.

Reporting Groups

	Description
ABT-335 + 40 mg Atorvastatin + 10 mg Ezetimibe	No text entered.
Placebo + 40 mg Atorvastatin + 10 mg Ezetimibe	No text entered.

Measured Values

	ABT-335 + 40 mg Atorvastatin + 10 mg Ezetimibe	Placebo + 40 mg Atorvastatin + 10 mg Ezetimibe
Number of Participants Analyzed [units: participants]	249	242
Mean Percent Change in Apolipoprotein CIII (apoCIII) From Baseline to Final Visit [units: Percent change] Mean ± Standard Error	-42.5 ± 1.22	-25.3 ± 1.23

Statistical Analysis 1 for Mean Percent Change in Apolipoprotein CIII (apoCIII) From Baseline to Final Visit

Groups ^[1]	All groups
Method ^[2]	ANCOVA
P Value ^[3]	< 0.001

[1]	Additional details about the analysis, such as null hypothesis and power calculation:
	Secondary endpoints were tested in fixed sequence. If superiority of ABT-335 + atorvastatin + ezetimibe treatment was demonstrated for primary endpoints, secondary endpoints were tested in ranked order of apoA1, VLDL-C, apoC3, non-HDL-C, apoB, and hsCRP at alpha = 0.05 level until 1 secondary endpoint failed to reach statistical significance.
[2]	Other relevant information, such as adjustments or degrees of freedom:
	Corresponding lipid value as the covariate and with effect for treatment group.
[3]	Additional information, such as whether or not the p-value is adjusted for multiple comparisons and the a priori threshold for statistical significance:
	No text entered.

6. Secondary:

Mean Percent Change in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) From Baseline to Final Visit [ Baseline to 12 weeks (Final Visit) ]

Show Outcome Measure 6

7. Secondary:

Mean Percent Change in Apolipoprotein B (apoB) From Baseline to Final Visit [ Baseline to 12 weeks (Final Visit) ]

Show Outcome Measure 7

8. Secondary:

Median Percent Change in High-Sensitivity C-Reactive Protein (hsCRP) From Baseline to Final Visit [ Baseline to 12 weeks (Final Visit) ]

Show Outcome Measure 8

Serious Adverse Events

Show Serious Adverse Events

Other Adverse Events

Show Other Adverse Events

More Information

Hide More Information

Certain Agreements:

Principal Investigators are NOT employed by the organization sponsoring the study.

There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

The agreement is:

	The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
	The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
	Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed. Restriction Description: Not to publish or present the results before the publication of the multi-center investigator paper, but in no event shall be so restricted after the expiration of twelve (12) months from completion of the studies at all sites. Any presentation or publication to be submitted to Sponsor (in Draft of the same) for Sponsor review and comment.

Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

Results Point of Contact:

Name/Title: Medical Information Specialist
Organization: Abbott Laboratories
phone: 800-633-9110

No publications provided

Responsible Party:	Abbott ( Maureen Kelly, MD )
Study ID Numbers:	M10-275
Study First Received:	March 14, 2008
Results First Received:	October 2, 2009
Last Updated:	November 16, 2009
ClinicalTrials.gov Identifier:	NCT00639158 History of Changes
Health Authority:	United States: Food and Drug Administration